Cisplatin/Irinotecan With Concurrent Radiation for Inoperable NSCLC

Inclusion Criteria:

* Histological or cytological documented NSCLC, including squamous cell carcinoma, adenocarcinoma, large cell carcinoma including large cell neuroendocrine carcinoma adenosquamous and sarcomatoid carcinomas.
* Patients with Pancoast tumors adjacent to a vertebral body are eligible as long as all gross disease can be encompassed in the radiation boost field. Pancoast tumor patients will be so-noted in the registry.
* Patients must be ≥ 18 years of age.
* Patients with Zubrod (ECOG) performance status ≤ 2.
* Adequate hematologic function defined as: ANC ≥ 1000/mm3, platelets ≥ 75,000/mm3, and hemoglobin ≥ 8 g/dL (prior to transfusions); adequate hepatic function defined as: total bilirubin ≤ 3.0 mg/dl, and adequate renal function defined as a serum creatinine level ≤ 2.0 mg/dl.
* Patients with weight loss ≤ 20% over the past 3 months.
* Patients with a pleural effusion that is proven cytologically negative or is too small to tap.
* Women of childbearing potential must agree to practice effective contraception throughout the study and for four weeks after completion of treatment.
* Pretreatment evaluations required for eligibility include:

  * A medical history, physical examination, and assessment of Zubrod performance status within 4 weeks prior to study entry.
  * CBC with differential and platelet count, and laboratory profile must be completed within 4 weeks prior to study entry.
  * CT scan of the chest or whole body PET (preferred), and a CT scan or MRI (preferred) of the brain within 4 weeks prior to study entry.
  * For women of childbearing potential, a serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) must be performed within a week prior to the start of protocol treatment.
  * Medical Oncology and Radiation Oncology consultation and approval.
* Patients must sign a study-specific consent form prior to study entry.

Exclusion Criteria:

* Small cell carcinomas or carcinoid histology.
* History of any malignancy in the past 2 years except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other in situ cancers.
* Prior systemic chemotherapy or radiotherapy that would interfere with delivery of treatment as outlined above as judged by the clinician.
* Cytologically malignant effusions.
* Radiographic evidence of metastatic disease.
* Active pulmonary infection not responsive to antimicrobial therapy.
* History of significant or symptomatic interstitial pneumonitis.
* Significant symptomatic cardiac disease, for example, unstable angina, uncompensated congestive heart failure, or uncontrolled cardiac ventricular arrhythmias.
* Patients with \> grade 2 neuropathy.
* Women who are pregnant or breast feeding, as treatment involves unforeseeable risks to the participant, embryo, fetus, or nursing infant; women with a positive pregnancy test on enrollment or prior to study drug administration.
* Women of childbearing potential who are unwilling to practice effective contraception throughout the study and for four weeks after completion of treatment.
* Patients who currently are participating in other clinical trials and/or who have participated in other clinical trials in the previous 30 days.